Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.

Schmid-Grendelmeier, Peter; J Gooderham, Melinda; Hartmann, Karin; N Konstantinou, George; Fellmann, Marc; Koulias, Christopher; Clibborn, Claire; Biswas, Pinaki; M Brunner, Patrick

doi:10.1111/all.15952

Public

Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.

Shared by NobleBlocks on Jan 1, 2024 • 12:00 AM UTC

Authors:

Peter Schmid-Grendelmeier

Melinda J Gooderham

Karin Hartmann

Abstract

BACKGROUND: Abrocitinib efficacy by comorbidity status in patients with moderate-to-severe atopic dermatitis (AD) has not been previously assessed. This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with AD and allergic comorbidities. METHODS: Data were pooled from p...

Subject

abrocitinib

asthma

atopic dermatitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!